WHO Targets Steatotic Liver Disease in Major Global Health Policy Shift

GENEVA, SWITZERLAND – February 03, 2026 – The World Health Organization is on the verge of officially recognizing steatotic liver disease (SLD) as a global health priority, a landmark move that could reshape the fight against non-communicable diseases (NCDs) worldwide. Today, at its 158th meeting, the WHO's Executive Board agreed to place a draft resolution on SLD on the agenda for the upcoming Seventy-Ninth World Health Assembly (WHA79) in May, strongly recommending it for adoption.

This decision represents a pivotal moment for a disease that affects hundreds of millions but has long been overshadowed by other NCDs. The resolution, titled “Steatotic liver disease: a missing piece in the global noncommunicable disease response,” signals a global consensus that the silent epidemic of liver disease can no longer be ignored. If adopted by the full assembly of Member States, the resolution would catalyze coordinated international action focused on prevention, early detection, and equitable access to care for a condition deeply intertwined with the global rise in obesity and diabetes.

A Silent Epidemic Comes Into Focus

Steatotic liver disease is an umbrella term for conditions defined by an unhealthy accumulation of fat in the liver. Its most common form, now known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), affects an estimated one-third of the global population. The condition is often asymptomatic in its early stages, progressing quietly until significant liver damage has occurred.

For years, it was referred to as non-alcoholic fatty liver disease (NAFLD), but a recent shift in nomenclature to MASLD better reflects its strong connection to metabolic syndrome—a cluster of conditions including obesity, type 2 diabetes, high blood pressure, and high cholesterol. In high-risk groups, such as individuals with type 2 diabetes, the prevalence of SLD can surge to over 70%.

When left unchecked, MASLD can advance to a more aggressive, inflammatory form called Metabolic Dysfunction-Associated Steatohepatitis (MASH). This inflammation can lead to severe liver scarring (fibrosis), cirrhosis, liver failure, and hepatocellular carcinoma, a type of liver cancer. The health burden is immense and growing; MASLD is projected to overtake Hepatitis C as the leading cause for liver transplants in many countries within the next decade. The global death toll from MASLD has already nearly doubled between 1990 and 2019, highlighting the urgent need for a cohesive public health response.

The 'Missing Piece' in Global Health Strategy

The title of the draft resolution aptly describes SLD's historical place in global health policy. For decades, the WHO's NCD strategy has revolved around the “big four”: cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes. While SLD is a direct consequence of the same risk factors driving the diabetes and obesity epidemics, it has never received the same level of strategic focus or resource allocation.

Advocates argue that this omission has created a critical blind spot in public health. By failing to address liver health directly, global NCD programs have missed a key opportunity for integrated prevention. The adoption of this resolution would formally recognize SLD as a major NCD in its own right, paving the way for its inclusion in national and international health strategies.

This integration is expected to foster more holistic and effective public health interventions. For example, national programs aimed at reducing sugar consumption and promoting physical activity to combat obesity would now be explicitly linked to preventing liver disease. This shift would not only elevate the profile of SLD but also strengthen the overall NCD response by promoting policies that address shared metabolic risk factors across multiple disease fronts.

The Four-Year Path to Global Recognition

Today's milestone is the culmination of a meticulous, four-year advocacy campaign spearheaded by the Global Liver Institute (GLI). Working in sustained collaboration with the Cabinet of the Egyptian Minister of Health and Population, GLI built a broad coalition to bring the issue to the forefront of the global health agenda.

“This is a turning point for the liver health community,” said Larry R. Holden, President and CEO of Global Liver Institute, in a statement. “For too long, steatotic liver disease has been absent from global NCD strategies, despite its close connection to obesity, diabetes, and cardiovascular disease. Today’s decision brings us one step closer to coordinated global action that prioritizes prevention, early diagnosis, and equitable access to care.”

The breadth of international support for the resolution is a testament to the success of this advocacy. The draft was co-sponsored by a diverse group of 16 Member States, including Armenia, Burundi, Chad, Chile, China, Egypt, Kuwait, Lebanon, Nigeria, Palestine, Paraguay, Qatar, Romania, the Russian Federation, Tunisia, and the United Republic of Tanzania.

“This achievement reflects the power of inclusive, international cooperation,” noted GLI Program Director Giacomo Donnini. He emphasized the collaborative effort that brought together “patients, scientists, clinicians, medical societies, policymakers, and the pharmaceutical industry” with the shared goal of giving SLD the global attention it requires.

From Resolution to Reality: What Comes Next

The WHO Executive Board’s recommendation is a crucial procedural step that significantly increases the likelihood of the resolution's formal adoption at the World Health Assembly in May 2026. While Member States can still propose amendments, a recommendation from the board signals strong preliminary consensus.

If adopted, the resolution will serve as a powerful mandate for action. It will urge Member States to develop national policies for SLD, improve surveillance to better understand the disease burden, train healthcare professionals for earlier diagnosis, and invest in public awareness campaigns. Crucially, it could also unlock new streams of funding for research into non-invasive diagnostics and effective treatments for MASH, which currently has limited pharmacological options.

For patients, the impact could be transformative. Increased awareness among primary care physicians may lead to earlier screening and lifestyle intervention, potentially halting disease progression before irreversible damage is done. Looking ahead, GLI and the Egyptian Minister of Health and Population plan to co-host a side event on Liver and Metabolic Health during WHA79 to continue building momentum and fostering global dialogue. The focus now shifts to May, when the world’s health ministers will have the opportunity to officially welcome steatotic liver disease into the global NCD framework, promising a healthier future for millions.